Mercer Global Advisors
PACB icon

Mercer Global Advisors’s Pacific Biosciences PACB Stock Holding History

Mercer Global Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.8K Buy
34,673
+14,010
+68% +$25.1K ﹤0.01% 3130
2025
Q4 		$38.6K Buy
20,663
+6,695
+48% +$12.9K ﹤0.01% 2808
2025
Q3 		$17.9K Buy
13,968
+1,581
+13% +$2.14K ﹤0.01% 2623
2025
Q2 		$15.4K Sell
12,387
-22,507
-65% -$26K ﹤0.01% 2230
2025
Q1 		$41.2K Buy
34,894
+11,068
+46% +$17K ﹤0.01% 2110
2024
Q4 		$43.6K Buy
+23,826
New +$46.5K ﹤0.01% 2090
2020
Q4 		– Sell
-10,165
Closed -$100K – 1383
2020
Q3 		$100K Buy
+10,165
New +$58.5K ﹤0.01% 1177
2020
Q2 		– Sell
-10,165
Closed -$31K – 1132
2020
Q1 		$31K Buy
+10,165
New +$41.6K ﹤0.01% 1069

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mercer Global Advisors's PACB Position: Q1 2026 in Review

Mercer Global Advisors increased its Pacific Biosciences (PACB) stake by 68% in Q1 2026, buying an estimated $25.1K and bringing the position to 34,673 shares worth $45.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3130.

Mercer Global Advisors first reported a position in PACB in Q1 2020 and has held it in 8 quarters since. The position peaked at $100K in Q3 2020. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Mercer Global Advisors held 34,673 shares of Pacific Biosciences worth $45.8K as of Q1 2026.
  • Mercer Global Advisors bought 14,010 Pacific Biosciences shares in Q1 2026, an estimated $25.1K.
  • Pacific Biosciences made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3130 holding.
  • Mercer Global Advisors first reported a position in Pacific Biosciences in Q1 2020 and has held it in 8 quarters since.
  • Mercer Global Advisors's Pacific Biosciences position peaked at $100K in Q3 2020.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.